Sir,
Ray D’ Alonzo earlier provided
background on a new directive to streamline our prescription drug
implementation strategy. It was a detailed presentation from the beginning
stages involving R&D and clinical trials all the way to our prescription
drugs reaching the consumer and hitting the market. To provide some
clarification, I will describe and reiterate his main selling points. Mr. D’
Alonzo understands the role technology plays in business and plans on creating
a more efficient process to save money and time.
Our prescription drug business
accounts for 11% of our total sales. Although, not an astonishing figure, this
sector of the business is highly profitable. There are many factors to consider
when discussing the life cycle of a specific drug. Obviously the R&D plays
a major role but the aspect of the process that needs improving is that of the
clinical trials and the way patient data is recorded. The current paper-process is cumbersome and
difficult to track. As you know CRA’s meet with investigator sites to work
together to ensure accurate data is inputted. This interaction is another major
cog in the wheel that needs improving. Significant time is wasted when the
paper is shipped and pertinent data is in “lock” phase. Information is not exchanged
instantaneously which creates backlog and overall poor project tracking.
Improvements can be sustained in nearly every aspect of the described
procedure, several of which will be outlined shortly.
To increase efficiency and
significantly shorten these process three options were considered; improve
existing paper-based process, digital imaging and web enabled/EDC (Electronic
Data Capture). The first option being to improve already existing paper based
process would require express mail shipments and increased staffing. Although,
these efforts would reduce overall time, it is rather expensive and regardless
paper in a digital world is slow. The second option, digital imaging, is nearly
impossible when considering the cost required to store data. There is a slight
increase in efficiency if this option was chosen, but time will show that
digital imaging won’t help increase employee and staff input of data. The third
option, which Mr. D’ Alonzo and I ultimately recommend is implementing a
Web-Enabled EDC system.
Web enabled EDC or electronic data
capture improves are timely prescription drug testing process significantly.
Investigator sites automatically put information on patients into the system.
Sponsor or CRA’s instantly get data, can quickly review and then can reject or
pass along to the next step. In some
situations, additional computer training will be required at the investigator
site and as with anything else there will be some slight resistance with
change. Regardless, sir, Wed Enabled EDC in some cases reduced the overall process
from 8 weeks to 1. This is an extraordinary increase in efficiency that should
not be ignored. I adamantly suggest the immediate implementation of this
technology and with your permission will head and properly execute it through
any growing pains.
Reflection/Review of Presentation (2/13/13)
Ladies
and Gentleman of the board after reviewing yesterday’s presentation, allow well
done, several adjustments could have been to make our decision easier. To start
a more accurate and clear depiction of cost would have been appropriate. I
believe several cost factors were not included and the presentation made it
difficult to track the root of some of our major expenses. Second, I believe a
biased view was formed on behalf of the presenters. They continuously labored
on the advantages of EDC, rather than fully explore every detailed alternative.
Regardless of several technicalities, the presentation was informative and
granted us the ability understand the situation at hand. In conclusion, I believe
it is in our best interest to immediately implement this relatively new
technology, EDC. The increased efficiency will allow us to gain a competitive
advantage and flourish in the future.
No comments:
Post a Comment